Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB
- 12 September 2020
- journal article
- research article
- Published by Springer Nature in Current HIV/AIDS Reports
- Vol. 17 (6) , 589-600
Abstract
Purpose of Review Despite broad uptake of antiretroviral therapy (ART), tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This review will outline short-course regimens for TB among patients with HIV. Recent Findings After many years without new agents, there is now active testing of many novel drugs to treat TB, both for latent infection and active disease. Though not all studies have included patients with HIV, many have, and there are ongoing trials to address key implementation challenges such as potent drug-drug interactions with ART. Summary The goal of short-course regimens for TB is to enhance treatment completion without compromising efficacy. Particularly among patients with HIV, studying these shortened regimens and integrating them into clinical care are of urgent importance. There are now multiple short-course regimens for latent infection and active disease that are safe and effective among patients with HIV.Keywords
This publication has 94 references indexed in Scilit:
- Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis PatientsPLOS ONE, 2013
- Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infectionEmerging Infectious Diseases, 2013
- Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy VolunteersJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionNew England Journal of Medicine, 2011
- Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2011
- New Regimens to Prevent Tuberculosis in Adults with HIV InfectionNew England Journal of Medicine, 2011
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006
- Effect of Tuberculosis Preventive Therapy on HIV Disease Progression and Survival in HIV-Infected AdultsHIV Research & Clinical Practice, 2006